The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2023,
Volume and Issue:
108(12), P. 3214 - 3222
Published: June 15, 2023
The
MPOWERED
core
trial
(NCT02685709)
and
open-label
extension
(OLE)
phase
investigated
long-term
efficacy
safety
of
oral
octreotide
capsules
(OOC)
in
patients
with
acromegaly.
Core
primary
endpoint
data
demonstrated
noninferiority
to
injectable
somatostatin
receptor
ligands
(iSRLs).
completers
were
invited
participate
the
OLE
phase.To
assess
OOC
acromegaly
who
previously
responded
tolerated
both
octreotide/lanreotide
completed
phase.The
unique
study
design
transitioning
between
iSRLs
allowed
within-patient
evaluations.
proportion
biochemical
responders
(insulin-like
growth
factor
I
<
1.3
×
upper
limit
normal)
at
end
each
year
entered
that
as
was
main
outcome
measure.At
1
end,
52/58
from
monotherapy
combination
therapy
groups
(89.7%;
95%
CI
78.8-96.1),
36/41
(87.8%;
73.8-95.9)
2,
29/31
(93.5%;
78.6-99.2)
3.
No
new
or
unexpected
signals
detected;
patient
withdrew
owing
treatment
failure.
Patients
transitioned
reported
improved
convenience/satisfaction
symptom
control.Patient-reported
support
for
first
time
randomized
iSRL
(who
iSRLs)
back
had
a
significant
effect
on
patients'
symptoms
score
prospective
cohort.
showed
maintenance
response
sustained
OOC.
Neuro-Oncology Advances,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 2, 2025
Abstract
Background
Aggressive
pituitary
tumors
and
carcinomas
represent
very
uncommon
entities
within
the
field
of
diseases.
Unfortunately,
treatment
options
after
progression
on
temozolomide
are
limited.
However,
advances
in
understanding
tumor
genetics
their
immunological
landscape
paving
way
for
new
targeted
molecular
therapies.
Methods
In
this
article,
we
present
an
overview
most
recent
literature,
focusing
specificities
role
current
treatments
future
perspectives
management
these
lesions.
Results
conclusions
remain
challenging
conditions
requiring
a
specific
multidisciplinary
approach
Pituitary
Tumor
Centers
excellence.
If
standard
therapy
fails,
Temozolomide
represents
first-line
option.
Peptide
Receptor
Radionuclide
Therapy
may
be
also
considered,
especially
expressing
Somatostatin
receptors.
When
progress
treatment,
prognosis
is
typically
poor,
among
various
second-line
ICIs
have
proven
to
effective.
Further
studies
exploring
potential
therapies
predictive
factors
aggressiveness
now
essential
improve
outcomes
patients.
Reviews in Endocrine and Metabolic Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 15, 2025
Abstract
Acromegaly
is
a
rare
condition,
and
often
diagnosis
delayed
by
several
years,
for
most
patients.
characterized
short
long-term
respiratory,
cardiovascular
metabolic
comorbidities,
with
possible
impact
on
mortality.
In
the
last
two
decades,
life
expectancy
has
progressively
increased
in
part
due
to
reduction
biochemically
active
disease,
multidisciplinary
treatment
approaches
complications,
availability
of
new
drugs.
Of
note,
leading
cause
mortality,
comorbidity,
been
replaced
cancer(s).
As
such,
neoplasms
more
frequently
observed
(colon,
thyroid,
breast,
prostate,
stomach)
patients
acromegaly
are
receiving
attention.
Chronic
exposure
growth
hormone
serum
levels
may
contribute
an
increase
occurrence
progression
cancers.
Various
efforts
have
made
determine
pathogenetic
mechanisms
involved.
However,
there
no
clear
medical-related
societal
agreement(s)
relation
screening
methods
or
timing
regarding
neoplasm(s)
acromegaly.
Additionally,
independent
dependent
risk
factor
data
lacking.
International/national
registries
could
help
lay
groundwork
better
study
cancer(s)
subsequently
lead
validate
appropriate
diagnostic
therapeutic
path
forward.
The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2024,
Volume and Issue:
109(6), P. 1433 - 1442
Published: Jan. 2, 2024
Abstract
Objective
To
review
experience
regarding
the
treatment
of
prolactinomas
by
endoscopic
endonasal
surgery
focusing
on
association
between
presurgical
dopamine
agonist
(DA)
and
perioperative
outcomes,
surgical
morbidities,
endocrine
pathological
characteristics.
Methods
A
single-center
series
290
cases
was
analyzed
retrospectively
clinical
data
were
collected.
Intratumoral
collagen
content
assessed
Masson
trichrome
staining.
Results
Tenacious
tumor
consistency
(27.8%
vs
9.8%,
P
<
.001)
more
common
in
DA-pretreated
patients
compared
with
who
underwent
initial
surgery.
Moreover,
macroadenomas
presented
intraoperative
blood
loss
(200
[100-400]
mL
175
[100-300]
mL;
=
.014),
longer
duration
(177
±
95
minutes
154
57
minutes;
.043),
morbidities
(19.4%
8.9%;
.034).
Additionally,
a
higher
volume
fraction
than
that
group
(23.6
2.2%
13.2
2.1%;
.001).
Correlation
analysis
revealed
close
correlation
cumulative
dose
bromocriptine
(BRC)
(r
0.438,
Regarding
microadenomas
showed
lower
proportion
remission
(86.7%
100%,
.047).
Conclusion
This
study
described
increased
difficulty
inferior
outcomes
associated
fibrosis
secondary
to
BRC
prolactinomas.
Neurosurgeons
should
note
may
render
subsequent
challenging.
Endocrinology and Metabolism,
Journal Year:
2023,
Volume and Issue:
38(6), P. 655 - 666
Published: Dec. 26, 2023
Since
our
discovery
in
2006
that
acromegaly
is
associated
with
an
increased
risk
of
vertebral
fractures,
many
authors
have
confirmed
this
finding
both
cross-sectional
and
prospective
studies.
Due
to
the
high
epidemiological
clinical
impact
newly
discovered
comorbidity
acromegaly,
topic
has
progressively
become
more
important
prominent
over
years,
pertinent
literature
been
enriched
by
new
findings
on
pathophysiology
treatment.
The
aim
narrative
review
was
discuss
these
novel
findings,
integrating
them
seminal
observations,
order
give
reader
updated
view
how
field
bone
developing,
from
strong
observations
a
mechanistic
understanding
possible
prevention
